2020
Fab’entech launches COVID-19 immunotherapy program - July 2020
​Fab’entech launches COVID-19 immunotherapy program - Phase I/II clinical trials scheduled for early 2021
2020
Fundarising from €8.5M - January 2020
Fab’entech raises €8.5M ($9.2M) to speed up development and marketing of passive immunotherapy treatments

2017

Update - July 2017
​Opportunities for Fab'entech in 2017

2015

Orphan drug designation - June 2015
Fab'entech has been granted with orphan medicinal product designation from the European Medicines Agency for Fabenflu®, its avian influenza (H5N1) product

GMP compliance - May 2015
Fab'entech has been granted with a certificate of GMP compliance by French National Agency for Medicines and Health Products Safety

Ebola program - February 2015
Fab'entech has started the development of an immunotherapy candidate targeting Ebola infections

2014

Fundraising - June 2014
Fab'entech has completed a 5 M€ fundraising

2012

Clinical trial - October 2012
Fab'entech has started a phase I clinical trial for its immunotherapy candidate targeting avian influenza (H5N1)

Grant program - February 2012
Fab'entech has been awarded with a grant of 7.1 M€ for its participation in the EMER-IT project